EFFECT OF RISPERIDONE ON HEART RATE DYNAMICS OF PATIENTS HAVING SCHIZOPHRENIA

N AMJAD; MIU HAQ; AR KHAN; R AHMED; S NAVEED

doi:10.54112/bcsrj.v2022i1.154

Authors

N AMJAD Department of Psychiatry, Shahida Islam Medical College Lodhran, Pakistan
MIU HAQ Department of Medicine, Shahida Islam Medical College Lodhran, Pakistan
AR KHAN Nishtar Medical University & Hospital Multan
R AHMED Department of Biochemistry, Independent Medical College Faisalabad, Pakistan
S NAVEED Fatima Memorial Hospital (FMH) Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2022i1.154

Keywords:

Risperidone, Heart rate variability, Schizophrenia, Psychosis

Abstract

Risperidone is a first-line antipsychotic drug for treating schizophrenia. It has antiadrenergic action but vhas a negligible impact on neurocardiac regulation. However, due to the relationship between cardiac autonomic regulation and a psychotic state, risperidone induces treatment-associated changes in heart rate variability (HRV). This Prospective study was designed to assess the effect of risperidone therapy on the heart rate dynamics of schizophrenic patients. Psychiatry & Medicine Department, Nishtar Medical Hospital, conducted this study from January 2021 to January 2022. After screening, patients with psychosis causing psychosocial impairment (PANSS score 70) were included in the study. Fifteen patients were selected after the screening. All were administered risperidone. A Control group having age and gender-matched subjects was selected, and ECG was done. Data from 15 controls and 15 patients were analyzed. Clinical Global Impressions-Severity of illness scale (CGI-S) and Positive and Negative Syndrome Scale (PANSS) were used for quantifying psychiatric symptoms. Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) was used to measure drug-associated movement disorders. The mean risperidone dose was 3.2± 0.8 mg/ day. Data collected after 6 weeks of treatment showed that the mean PANSS
score, positive symptoms subscale score, negative symptoms subscale score, CGI-S score and general psychopathology score decreased significantly (p< 0.001). Comparison of HRV parameters between the control group (healthy subjects) and unmedicated patients showed a significant group effect (p<0.001). Evaluation of the association between the severity of psychotic symptoms and HRV measures shows the negative correlation between PANSS positive symptoms score changes and SDNN changes (p= .012).Risperidone treatment in acutely ill schizophrenic patients leads to an increase in cardio-vagal activity, thus causing improvement in sympathovagal imbalance.

Downloads

Download data is not yet available.

References

Baik, S. Y., Kim, C., Kim, S., Yook, D.-W., Kim, H. S., Chang, H., and Lee, S.-H. (2019). The moderating effect of heart rate variability on the relationship between alpha asymmetry and depressive symptoms. Heliyon5, e01290.

BHARGAVA, V., and ACHARYA, C. (2019). Comparing the Effects of Olanzapine and Aripiprazole in Rat Animal Model using Heart Rate Variability: An Emerging Parameter of Cardiovascular Safety. Journal of Clinical & Diagnostic Research13.

Dijkhuis, R. R., Ziermans, T., van Rijn, S., Staal, W., and Swaab, H. (2019). Emotional arousal during social stress in young adults with autism: Insights from heart rate, heart rate variability and self-report. Journal of autism and developmental disorders49, 2524-2535.

Edinoff, A. N., Ellis, E. D., Nussdorf, L. M., Hill, T. W., Cornett, E. M., Kaye, A. M., and Kaye, A. D. (2022). Antipsychotic Polypharmacy-Related Cardiovascular Morbidity and Mortality: A Comprehensive Review. Neurology International14, 294-309.

Fernandez, A. (2018). Neurodevelopmental alterations in a mouse model of maternal immune activation, Aix-Marseille.

Heiss, S., Vaschillo, B., Vaschillo, E. G., Timko, C. A., and Hormes, J. M. (2021). Heart rate variability as a biobehavioral marker of diverse psychopathologies: A review and argument for an "ideal range". Neuroscience & Biobehavioral Reviews121, 144-155.

Kheder, S. H., Heller, J., Bär, J., Wutzler, A., Menge, B., and Juckel, G. (2018). Autonomic dysfunction of gastric motility in major depression. Journal of Affective Disorders226, 196-202.

Lee, J. S., Yun, J.-Y., Kang, S. H., Lee, S. J., Choi, J.-H., Nam, B., Lee, S.-H., Chung, Y.-C., and Kim, C.-H. (2020). Korean Medication Algorithm for Schizophrenia 2019, second revision: treatment of psychotic symptoms. Clinical Psychopharmacology and Neuroscience18, 386.

Moon, S.-Y., Kim, M., Lho, S. K., Oh, S., Kim, S. H., and Kwon, J. S. (2021). Systematic review of the neural effect of electroconvulsive therapy in patients with schizophrenia: hippocampus and insula as the key regions of modulation. Psychiatry Investigation18, 486.

Newton, R., Rouleau, A., Nylander, A.-G., Loze, J.-Y., Resemann, H. K., Steeves, S., and Crespo-Facorro, B. (2018). Diverse definitions of the early course of schizophrenia—a targeted literature review. npj Schizophrenia4, 1-10.

Refisch, A., Chung, H.-Y., Komatsuzaki, S., Schumann, A., Muehleisen, T. W., Noethen, M. M., Huebner, C. A., and Baer, K.-J. (2021). A common variation in HCN1 is associated with heart rate variability in schizophrenia. Schizophrenia research229, 73-79.

Robinson, D. G., Gallego, J. A., John, M., Hanna, L. A., Zhang, J.-P., Birnbaum, M. L., Greenberg, J., Naraine, M., Peters, B. D., and McNamara, R. K. (2019). A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone. Schizophrenia research204, 295-303.

Schulz, S., Haueisen, J., Bär, K.-J., and Voss, A. (2019). Altered causal coupling pathways within the central-autonomic-network in patients suffering from schizophrenia. Entropy21, 733.

Schulz, S., Haueisen, J., Bär, K.-J., and Voss, A. (2020). The cardiorespiratory network in healthy first-degree relatives of schizophrenic patients. Frontiers in neuroscience14, 617.

Tajiri, M., Suzuki, Y., Sugai, T., Tsuneyama, N., and Someya, T. (2018). Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia. Plos one13, e0199922.

Vickers, M., Ramineni, V., Malacova, E., Eriksson, L., McMahon, K., Moudgil, V., Scott, J., and Siskind, D. (2022). Risk factors for clozapine‐induced myocarditis and cardiomyopathy: A systematic review and meta‐analysis. Acta Psychiatrica Scandinavica145, 442-455.